Stokes Family Office LLC Cuts Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Stokes Family Office LLC lowered its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 29.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 855 shares of the medical equipment provider’s stock after selling 357 shares during the quarter. Stokes Family Office LLC’s holdings in Intuitive Surgical were worth $288,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. WCM Investment Management LLC acquired a new stake in shares of Intuitive Surgical during the 4th quarter worth about $575,536,000. International Assets Investment Management LLC boosted its position in Intuitive Surgical by 32,360.5% during the fourth quarter. International Assets Investment Management LLC now owns 686,865 shares of the medical equipment provider’s stock worth $231,721,000 after acquiring an additional 684,749 shares during the last quarter. Alphinity Investment Management Pty Ltd grew its stake in Intuitive Surgical by 113.2% in the 4th quarter. Alphinity Investment Management Pty Ltd now owns 1,276,158 shares of the medical equipment provider’s stock worth $430,525,000 after acquiring an additional 677,455 shares during the period. J.P. Morgan Private Wealth Advisors LLC acquired a new position in Intuitive Surgical in the 3rd quarter valued at $178,667,000. Finally, Quadrature Capital Ltd lifted its stake in shares of Intuitive Surgical by 466.2% during the 3rd quarter. Quadrature Capital Ltd now owns 340,644 shares of the medical equipment provider’s stock worth $99,601,000 after purchasing an additional 280,480 shares during the period. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Price Performance

NASDAQ:ISRG traded up $3.71 during mid-day trading on Friday, reaching $381.36. The stock had a trading volume of 1,028,858 shares, compared to its average volume of 1,492,254. The stock’s 50 day simple moving average is $385.56 and its two-hundred day simple moving average is $348.56. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $403.76. The company has a market capitalization of $135.27 billion, a price-to-earnings ratio of 68.84, a price-to-earnings-growth ratio of 4.88 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.10. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The business had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. During the same period in the prior year, the company posted $1.00 EPS. The business’s revenue was up 11.5% compared to the same quarter last year. Sell-side analysts anticipate that Intuitive Surgical, Inc. will post 4.8 EPS for the current fiscal year.

Insider Buying and Selling

In related news, VP Marshall Mohr sold 108,790 shares of the stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total value of $41,892,853.20. Following the completion of the transaction, the vice president now directly owns 26,877 shares of the company’s stock, valued at approximately $10,349,795.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Intuitive Surgical news, VP Marshall Mohr sold 108,790 shares of the firm’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $385.08, for a total transaction of $41,892,853.20. Following the transaction, the vice president now owns 26,877 shares of the company’s stock, valued at approximately $10,349,795.16. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, President David J. Rosa sold 80,710 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $389.28, for a total transaction of $31,418,788.80. Following the transaction, the president now owns 163,399 shares in the company, valued at approximately $63,607,962.72. The disclosure for this sale can be found here. Insiders have sold a total of 226,928 shares of company stock valued at $87,833,828 in the last quarter. Company insiders own 0.90% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on ISRG. Citigroup raised their price target on Intuitive Surgical from $428.00 to $462.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Stifel Nicolaus lifted their price target on shares of Intuitive Surgical from $420.00 to $430.00 and gave the company a “buy” rating in a report on Monday, April 8th. Piper Sandler upped their price objective on Intuitive Surgical from $425.00 to $435.00 and gave the stock an “overweight” rating in a report on Friday, April 19th. Royal Bank of Canada lifted their target price on Intuitive Surgical from $400.00 to $432.00 and gave the company an “outperform” rating in a report on Wednesday, January 24th. Finally, Wells Fargo & Company boosted their target price on Intuitive Surgical from $363.00 to $416.00 and gave the stock an “overweight” rating in a report on Friday, January 19th. Five equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $396.17.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.